ADGM Overview

Adagio Medical Holdings, Inc. is a medical device company. The Company is focused on developing and commercializing products for the treatment of cardiac arrhythmias with catheter-based ultra-low temperature ablation (ULTA) technology, formerly known as ultra-low temperature cryoablation (ULTC) technology. Its initial focus is on the treatment of ventricular tachycardia (VT), which is a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart’s lower chambers, or ventricles, potentially leading to impaired blood flow and, if sustained, it can be fatal. Its ULTA products are purpose-built to treat patients with VT and are designed to address the unique anatomy of the ventricle and the specific needs of the VT patient. Its catheters and consoles are designed to create titratable, large, durable, deep lesions within the ventricle through a stable, endocardial or inside the heart approach with no required irrigation.

Wall Street analysts forecast ADGM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADGM is4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Adagio Medical Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

Adagio Medical Holdings Inc. EPS for the last quarter amounts to -0.16 USD, decreased -95.21

Adagio Medical Holdings Inc (ADGM) has 41 emplpoyees as of May 11 2026.

Today ADGM has the market capitalization of 21.66M USD.